The most striking example is seen for NDM patients with a mutation in the KATP channel genes, who can be treated effectively with oral sulfonylureas that directly bind the SUR1 regulatory subunit of the channel, rather than requiring life-long insulin therapy which usually provides poor glycemic contol [4], [5], [6]. This evidence concerns the gene ABCC8 and neonatal diabetes mellitus.